Article thumbnail

In vitro characterization of cells derived from chordoma cell line U-CH1 following treatment with X-rays, heavy ions and chemotherapeutic drugs

By Takamitsu A Kato, Akihisa Tsuda, Mitsuru Uesaka, Akira Fujimori, Tadashi Kamada, Hirohiko Tsujii and Ryuichi Okayasu
Topics: Research
Publisher: BioMed Central
OAI identifier:
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles


  1. (2005). A: Alterations of G1-S checkpoint in chordoma: the prognostic impact of p53 overexpression. Cancer
  2. (2009). AM: Potential therapeutic targets for chordoma: PI3K/AKT/TSC1/TSC2/mTOR pathway.
  3. (2010). and LET-painting with particle therapy. Acta Oncol
  4. (1999). Biophysical characteristics of HIMAC clinical irradiation system for heavy-ion radiation therapy.
  5. (2003). Carbon ion radiotherapy for chordomas and low-grade chondrosarcomas of the skull base. Results in 67 patients. Strahlenther Onkol
  6. (1996). Chordoma: long-term follow-up after radical photon irradiation. RadiotherOncol
  7. (2000). CM: Tumour oxygenation levels correlate with dynamic contrast-enhanced magnetic resonance imaging parameters in carcinoma of the cervix. Radiother Oncol
  8. (1981). Detection of a common feature in several human tumor cell lines–a 53,000-dalton protein. Proc Natl Acad Sci USA
  9. (2006). Effectiveness of cetuximab/gefitinib in the therapy of a sacral chordoma. Onkologie
  10. (2003). G: A small prospective study of chordomas treated with radiotherapy and razoxane. Strahlen ther Onkol
  11. (2009). Gagnon GJ: Treatment of chordomas with CyberKnife: georgetown university experience and treatment recommendations. Neurosurgery
  12. (1988). Gennari L: Chordoma: natural history and treatment results in 33 cases.
  13. (2001). Genome-wide analysis of sixteen chordomas by comparative genomic hybridization and cytogenetics of the first human chordoma cell line, UCH1. Genes Chromosomes Cancer
  14. (1996). GH: WAF1/CIP1 increases the susceptibility of p53 non-functional malignant glioma cells to cisplatin-induced apoptosis. Oncogene
  15. (2006). Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature
  16. (2008). Gokaslan ZL: Chordoma of the spinal column.
  17. (1997). H: Irradiation of mixed beam and design of spread-out Bragg peak for heavy-ion radiotherapy. Radiat Res
  18. (2010). Heidelberg Ion Therapy Center (HIT): Initial clinical experience in the first 80 patients. Acta Oncol
  19. (2008). HS: F-18 FDG PET/CT evaluation of sacrococcygeal chordoma. Clin Nucl Med
  20. (1979). Huvos AG: Spinal chordomas.
  21. (1976). Jr: Lumbosacral chordoma. Prognostic factors and treatment. Spine (Phila Pa
  22. (1994). Kastan MB: DNA damage responses: p53 induction, cell cycle perturbations, and apoptosis. Cold Spring Harb Symp Quant Biol
  23. (1997). Kastan MB: Role of p53 in apoptosis. Adv Pharmacol
  24. (1994). Kastan MB: The p53-dependent G1 cell cycle checkpoint pathway and ataxia-telangiectasia. Cancer Res
  25. (2005). LH: Phase II study of 9-nitro-camptothecin in patients with advanced chordoma or soft tissue sarcoma. JClinOncol
  26. (2006). MF: Defective p53 response and apoptosis associated with an ataxia-telangiectasia-like phenotype. Cancer Res
  27. (2004). Mutant p53 exerts a dominant negative effect by preventing wild-type p53 from binding to the promoter of its target genes. Oncogene
  28. (2005). Prognostic value of tumor oxygenation in 397 head and neck tumors after primary radiation therapy. An international multi-center study. Radiother Oncol
  29. (1995). Radiation therapy for chordomas of the base of skull and cervical spine: patterns of failure and outcome after relapse.
  30. (1968). RBE and OER of the heavy ionizing particles released during 10beta-neutron capture therapy. Rev Latino am Microbiol Parasitol (Mex)
  31. (2005). Rofstad EK: Fluctuations in pO2 in poorly and well-oxygenated spontaneous canine tumors before and during fractionated radiation therapy. Radiother Oncol
  32. (2004). Tatezaki S: Carbon ion radiotherapy for unresectable sacral chordomas. Clin Cancer Res
  33. (2010). Tatezaki S: Effect of carbon ion radiotherapy for sacral chordoma: results of Phase I-II and Phase II clinical trials.
  34. (1993). TL: Charged particle irradiation of sacral chordomas.
  35. (2003). Treatment planning intercomparison for spinal chordomas using intensity-modulated photon radiation therapy (IMRT) and carbon ions. Phys Med Biol
  36. (2006). Tsujii H: Examination of GyE system for HIMAC carbon therapy.
  37. (1968). WK: X-ray sensitivity of synchronized Chinese hamster cells irradiated during hypoxia. Radiat Res